FluoGuide A/S Stock price




Advanced Medical Equipment & Technology

Delayed Nasdaq Stockholm 04:32:28 2023-12-11 am EST Intraday chart for FluoGuide A/S 5-day change 1st Jan Change
68.4 SEK -0.87% +13.62% +82.40%


Sales 2022 * - Sales 2023 * - Capitalization 548M 79.21M 830M
Net income 2022 -27M -3.9M -40.86M Net income 2023 * -24M -3.47M -36.32M EV / Sales 2022
Net cash position 2022 26.01M 3.76M 39.37M Net cash position 2023 * 350M 50.55M 530M EV / Sales 2023 *
P/E ratio 2022
P/E ratio 2023 *
Employees 6
Yield 2022
Yield 2023 *
Free-Float 58.01%
More Fundamentals * Assessed data
Dynamic Chart
FluoGuide A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer CI
FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference CI
Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague CI
FluoGuide A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer CI
FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer CI
Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer CI
FluoGuide A/S Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
FluoGuide A/S Appoints Michael Thyrring Engsig as Member of the Board of Directors CI
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2022 CI
FluoGuide A/S Updates on Recruitment in Phase IIb Aggressive Brain Cancer Trial with FG001 CI
Sweden's FluoGuide Names Successor as CFO Resigns MT
FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer CI
FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer CI
More news
1 day+0.58%
1 week+10.22%
Current month+7.81%
1 month-18.82%
3 months-25.00%
6 months-21.23%
Current year+84.00%
More quotes
1 week
Extreme 52.6
1 month
Extreme 52.6
Current year
Extreme 37.5
1 year
Extreme 36.4
3 years
Extreme 35.5
5 years
Extreme 4.1
10 years
Extreme 4.1
More quotes
Managers TitleAgeSince
Founder 60 2018
Chief Executive Officer 59 2017
Director of Finance/CFO 58 Feb. 01
Members of the board TitleAgeSince
Director/Board Member 62 2018
Director/Board Member 52 2020
Chairman 63 2019
More insiders
Date Price Change Volume
23-12-11 68.4 -0.87% 5 317
23-12-08 69 +0.58% 58,640
23-12-07 68.6 +10.65% 27,491
23-12-06 62 +9.93% 40,018
23-12-05 56.4 -6.31% 70,583

Delayed Quote Nasdaq Stockholm, December 08, 2023 at 11:29 am EST

More quotes
FluoGuide A/S is a Denmark-based biotechnology company focused on developing drugs for maximizing surgical outcomes by making cancer fluorescent. The Company is a provider of solutions for maximizing surgical outcome through intelligent targeting. FluoGuide develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The Company's main product, FG001, is designed using FluoGuide's uPAR technology platform to improve surgical precision by illuminating cancer cells intraoperatively. FluoGuide explores FG001 in three other severe cancer indications, namely lung, head & neck, meningioma and low grade glioma.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock FluoGuide A/S - Nasdaq Stockholm
As early as today, start finding the best investment opportunities!
Optimize my profits